	US 12,319,747 B2
	Methods of using anti-SP17 immunotherapeutics
Seah Lim, Wilmington, DE (US)
Assigned to MEDICOVESTOR, INC., Wilmington, DE (US)
Filed by Medicovestor, Inc., Wilmington, DE (US)
Filed on Jan. 9, 2024, as Appl. No. 18/408,377.
Claims priority of provisional application 63/524,809, filed on Jul. 3, 2023.
Prior Publication US 2025/0011460 A1, Jan. 9, 2025
Int. Cl. C07K 16/30 (2006.01); A61P 35/00 (2006.01); C12N 15/10 (2006.01); C12Q 1/6886 (2018.01); G01N 33/68 (2006.01)

CPC C07K 16/30 (2013.01) [A61P 35/00 (2018.01); C12N 15/1096 (2013.01); C12Q 1/6886 (2013.01); G01N 33/6893 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/46 (2013.01)]

19 Claims

1. A method to modulate cells that express Sp17 in a human subject, comprising administering an immunotherapeutic agent to the human subject, wherein:

the immunotherapeutic agent comprises a first variable domain that comprises a VH CDR1 region comprising SEQ ID NO: 5, a VH CDR2 region comprising SEQ ID NO: 6, and a VH CDR3 region comprising SEQ ID NO: 7; and

a second variable domain that comprises a VL CDR1 region comprising SEQ ID NO: 8, a VL CDR2 region comprising SEQ ID NO: 9, and a VL CDR3 region comprising SEQ ID NO: 10; and

wherein the immunotherapeutic agent binds human sperm protein 17 (Sp17).